Avista VP granted restricted and performance shares
Avista Corp vice president Joshua D. DiLuciano reported new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avista Corp vice president Joshua D. DiLuciano reported new equity awards. On February 9, 2026, he received 1,756 shares of Common Stock as a restricted share grant at $40.99 per share, bringing his directly held common stock to 12,157.0699 shares.
He was also granted 4,100 performance shares, priced at $40.99, representing potential common stock based on performance goals, with 4,100 derivative securities owned directly after the grant. The restricted shares vest one-third per year over three years, while the performance share cycles run three years, with shares issued only if performance measures are met.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Shares Grant - 2026 | 4,100 | $40.99 | $168K |
| Grant/Award | Common Stock - Restricted Shares Grant 2026 | 1,756 | $40.99 | $72K |
Footnotes (3)
- F1. Restricted Shares vest 1/3 each year over a 3-year period and are payable in Avista Corp. Common Stock at the end of each year in the 3-year period.
- F2. No conversion price. Shares awarded if performance measure is met.
- F3. Each performance cycle is 3 years in length. Shares will be issued at the end of each 3-year cycle if performance measure is met.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider equity awards did Avista Corp (AVA) report for Joshua D. DiLuciano?
Is Joshua D. DiLuciano’s Avista (AVA) ownership direct or indirect after these grants?
AI-generated analysis. How Rhea-AI works. Not financial advice.